Klotho Neurosciences Free Cash Flow 2023-2024 | KLTO

Klotho Neurosciences free cash flow from 2023 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.

Klotho Neurosciences Free Cash Flow 2023-2024 | KLTO

Klotho Neurosciences free cash flow from 2023 to 2024. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$168.1B
Vertex Pharmaceuticals (VRTX)$119.2B
Regeneron Pharmaceuticals (REGN)$113.7B
Gilead Sciences (GILD)$102.4B
Bristol Myers Squibb (BMY)$101.3B
CSL (CSLLY)$95.4B
GSK (GSK)$84.1B
Alnylam Pharmaceuticals (ALNY)$35B
Argenex SE (ARGX)$32.8B
Biogen (BIIB)$27.5B
BioNTech SE (BNTX)$27.5B
Moderna (MRNA)$24.5B
BeiGene (BGNE)$20.1B
Illumina (ILMN)$20.1B
Genmab (GMAB)$15.8B
BioMarin Pharmaceutical (BMRN)$13.1B
Vaxcyte (PCVX)$12.7B
Exact Sciences (EXAS)$12.5B
Insmed (INSM)$12.5B
Incyte (INCY)$12.2B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.9B
QIAGEN (QGEN)$10.1B
Bio-Rad Laboratories (BIO.B)$9.1B
Roivant Sciences (ROIV)$8.7B
Ascendis Pharma (ASND)$8.5B
Legend Biotech (LEGN)$7.9B
Intra-Cellular Therapies (ITCI)$7.9B
Repligen (RGEN)$7.8B
Exelixis (EXEL)$7.4B